5-Methyltetrahydrofolate Administration Is Associated with Prolonged Survival and Reduced Inflammation in ESRD Patients | Zendy

Giuseppe Cianciolo | Zendy; Gaetano La Manna | Zendy; L. Colì | Zendy; Gabriele Donati | Zendy; Francesca D’Addio | Zendy; Elisa Persici | Zendy; Giorgia Comai | Zendy; Mary Lou Wratten | Zendy; Ada Dormi | Zendy; Vilma Mantovani | Zendy; Gabriele Grossi | Zendy; Sergio Stefoni | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

5-Methyltetrahydrofolate Administration Is Associated with Prolonged Survival and Reduced Inflammation in ESRD Patients

Author(s) -

Giuseppe Cianciolo,

Gaetano La Manna,

L. Colì,

Gabriele Donati,

Francesca D’Addio,

Elisa Persici,

Giorgia Comai,

Mary Lou Wratten,

Ada Dormi,

Vilma Mantovani,

Gabriele Grossi,

Sergio Stefoni

Publication year - 2008

Publication title -

american journal of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.394

H-Index - 85

eISSN - 1421-9670

pISSN - 0250-8095

DOI - 10.1159/000142363

Subject(s) - hyperhomocysteinemia , medicine , homocysteine , hemodialysis , gastroenterology , risk factor , peritoneal dialysis , dialysis , c reactive protein , surgery , inflammation

Hemodialysis (HD) patients have a greatly increased risk of cardiovascular morbidity and mortality. For this reason, attempts are often made to normalize hyperhomocysteinemia. This randomized prospective study sought to determine which risk factors are predictors of mortality and whether high doses of folates or 5-methyltetrahydrofolate (5-MTHF) could improve hyperhomocysteinemia and survival in HD patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research